We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

A Paper-Based Nucleic Acid Testing Device for Rapid Diagnosis of Mosquito-Borne Viral Diseases

By LabMedica International staff writers
Posted on 22 Sep 2020
Print article
Image: The Aedes aegypti mosquito can spread various tropical diseases including dengue, zika, and chikungunya, which have similar symptoms (Photo courtesy of Gwangju Institute of Science and Technology)
Image: The Aedes aegypti mosquito can spread various tropical diseases including dengue, zika, and chikungunya, which have similar symptoms (Photo courtesy of Gwangju Institute of Science and Technology)
An all-in-one nucleic acid testing device loaded into a paper chip forms the basis for a simple, rapid diagnostic test for a range of mosquito-borne viral diseases.

COVID-19 is not the only disease out there. Several tropical fever viruses transmitted by mosquitoes including zika, dengue, and chikungunya, are becoming a serious problem in global public health. The three diseases have similar symptoms, making early diagnosis particularly difficult without complex molecular diagnostic equipment. Thus, simple diagnostic tools are strongly required to monitor and prevent these diseases.

In this regard, investigators at the Gwangju Institute of Science and Technology (South Korea) developed LAMDA (lab-on-paper for all-in-one molecular diagnostics), which is a mini laboratory on a paper strip. LAMDA comprises a complete LAMP system in a paper strip. LAMP (Loop-mediated isothermal amplification) is a single-tube technique for the isothermal amplification of DNA and is a low-cost alternative to detect certain diseases. In contrast to the polymerase chain reaction (PCR) technique, in which the reaction is carried out with a series of alternating temperature steps or cycles, isothermal amplification is carried out at a constant temperature, and does not require a thermal cycler. Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) combines LAMP with a reverse transcription step to allow the detection of RNA.

The novel LAMDA platform concentrates the entire process of nucleic acid testing including sampling, extraction, amplification, and detection into a single paper chip. To use the LAMDA test, a drop of blood serum and some drops of distilled water are applied to two pads. The liquids flow through the paper strip horizontally and reach the base of a small vertical stack of layers that extracts all the RNA from the sample and multiplies any viral RNA of the three diseases that might be present. The top layer of the vertical stack comprises individual "reaction" patches, each designed to detect one of the three diseases. After the RNA is extracted, it flows up to the top layer, where LAMP reactions cause the fluorescent indicators on a patch to become dim if its target viral RNA is present in the sample.

Results obtained with the LAMDA platform revealed that three targets, zika virus, dengue virus, and chikungunya virus, in human serum could be detected simultaneously on the all-in-one paper chip within 60 minutes at 65 degrees Celsius. The all-in-one paper chip could be used as a real-time quantitative assay for five to 5000 copies of zika virus RNA, and LAMDA performance was demonstrated with five clinical specimens of zika and dengue virus.

Senior author Dr. Min-Gon Kim, professor of chemistry at the Gwangju Institute of Science and Technology, said "We believe that with minor modifications, such as a portable system to maintain reaction temperature at 65 degrees Celsius and a means to detect the fluorescence change with a smartphone, the proposed all-in-one paper chip can become a portable, low-cost, user-friendly, sensitive, and specific nucleic acid test platform with great potential in point-of-care diagnostics. We certainly hope that our approach and achievements with LAMDA will be helpful to advance research and development of on-site medical diagnostic tools,"

The LAMDA diagnostic platform was described in the October 1, 2020, online edition of the journal Biosensors and Bioelectronics.

Related Links:
Gwangju Institute of Science and Technology

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.